Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
158.99B
Market cap158.99B
Price-Earnings ratio
36.80
Price-Earnings ratio36.80
Dividend yield
6.19%
Dividend yield6.19%
Average volume
33.53M
Average volume33.53M
High today
$27.98
High today$27.98
Low today
$27.57
Low today$27.57
Open price
$27.76
Open price$27.76
Volume
15.86M
Volume15.86M
52 Week high
$29.21
52 Week high$29.21
52 Week low
$23.58
52 Week low$23.58

Stock Snapshot

The current Pfizer(PFE) stock price is $27.90, with a market capitalization of 158.99B. The stock trades at a price-to-earnings (P/E) ratio of 36.80 and offers a dividend yield of 6.19%.

On 2026-09-09, Pfizer(PFE) stock traded between a low of $27.57 and a high of $27.98. Shares are currently priced at $27.90, which is +1.2% above the low and -0.3% below the high.

The Pfizer(PFE)'s current trading volume is 15.86M, compared to an average daily volume of 33.53M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $29.21 and a 52-week low of $23.58.

In the last year, Pfizer(PFE) shares hit a 52-week high of $29.21 and a 52-week low of $23.58.

PFE News

Nasdaq 7h
Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?

Pfizer PFE stock has risen 8.6% in the past three months as investors have gained confidence in the company’s ability to stabilize earnings and offset the conti...

Pfizer Stock Rises Almost 9% in 3 Months: Time to Buy, Hold or Exit?
Nasdaq 22h
Why Pfizer Stock Was so Healthy in August

Key Points It also advanced a pair of promising developmental drugs. Investors have grown impatient waiting for the company's next blockbuster product. 10 st...

Why Pfizer Stock Was so Healthy in August
Nasdaq 1d
Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

Key Points Pharmaceutical giant AbbVie has a longer history of dividend growth than Pfizer. Pfizer faces greater exposure this decade to the loss of patent ex...

Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

Analyst ratings

61%

of 28 ratings
Buy
32.1%
Hold
60.7%
Sell
7.1%

More PFE News

Simply Wall St 2d
Pfizer Hands Broad Rights On CD228V In New Oncology Licensing Deal - simplywall.st

...

Pfizer Hands Broad Rights On CD228V In New Oncology Licensing Deal - simplywall.st
TipRanks 2d
The Second Act of Biotech

Pfizer sells dopamine. Moderna made the COVID vaccine. Both are betting their next decade on medicines that barely existed when their stocks peaked. The pandemi...

TipRanks 4d
Pfizer Ramps Up Obesity And Eczema Bets, Investors Watch

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Pfizer Inc. is quietly reshaping its long‑term growt...

Nasdaq 5d
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Key Points AbbVie leverages a strong pipeline in immunology and oncology to drive nearly $61.2 billion in annual revenue. Pfizer maintains a diverse portfolio...

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
TipRanks 5d
Pfizer Steps Up in Obesity Race With New Phase 3 Berobenatide Trial in Japan

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) has launched a Phase 3 study in Japan called VESPER-JW to test once-wee...

TipRanks 5d
Pfizer’s Migraine Tablet Study Wraps Up, Supporting Pipeline Flexibility for PFE Investors

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) has completed a Phase 1 study called “A PHASE 1, OPEN LABEL, SINGLE DOS...

24/7 Wall St. 5d
Pfizer's Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?

Investing Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying? Pfizer shareholders are collecting a 6% yield while the stock bleeds value, a...

Pfizer's Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.